Literature DB >> 22537994

Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.

Morven S Edwards1, Heidi J Lane, Sharon L Hillier, Marcia A Rench, Carol J Baker.   

Abstract

The duration of functional activity of group B streptococcal (GBS) glycoconjugate vaccine-induced capsular polysaccharide-specific (CPS) IgG was evaluated among healthy adult responders. Opsonophagocytic activity declined significantly from a 4-week post-immunization peak, but substantial functional activity, exceeding 1 log(10) reduction in GBS cfu/mL, was retained at 18 months to 2 years post-immunization for each GBS type assessed. The persistence of functional antibody activity when GBS CPS-specific IgG concentrations decline, although remaining significantly higher than pre-immunization levels, suggests that long-term protection may be expected from candidate GBS glycoconjugates administered to this population.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537994      PMCID: PMC3392193          DOI: 10.1016/j.vaccine.2012.04.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.

Authors:  Birgit Simell; Arja Vuorela; Nina Ekström; Arto Palmu; Antti Reunanen; Seppo Meri; Helena Käyhty; Merja Väkeväinen
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

2.  Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.

Authors:  F Y Lin; J B Philips; P H Azimi; L E Weisman; P Clark; G G Rhoads; J Regan; N F Concepcion; C E Frasch; J Troendle; R A Brenner; B M Gray; R Bhushan; G Fitzgerald; P Moyer; J D Clemens
Journal:  J Infect Dis       Date:  2001-08-31       Impact factor: 5.226

3.  Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery.

Authors:  J R Campbell; S L Hillier; M A Krohn; P Ferrieri; D F Zaleznik; C J Baker
Journal:  Obstet Gynecol       Date:  2000-10       Impact factor: 7.661

4.  Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Authors:  Shabir A Madhi; Avy Violari; Keith P Klugman; Gina Lin; James A McIntyre; Anne von Gottberg; Patrick Jean-Philippe; Mark F Cotton; Peter Adrian
Journal:  Vaccine       Date:  2011-07-23       Impact factor: 3.641

5.  Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  Carol J Baker; Marcia A Rench; Pamela McInnes
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

6.  Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.

Authors:  M D Snape; D F Kelly; S Lewis; C Banner; L Kibwana; C E Moore; L Diggle; T John; L M Yu; R Borrow; A Borkowski; C Nau; A J Pollard
Journal:  BMJ       Date:  2008-06-05

Review 7.  Pneumococcal vaccination and revaccination of older adults.

Authors:  Andrew S Artz; William B Ershler; Dan L Longo
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

8.  Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.

Authors:  Carol J Baker; Lawrence C Paoletti; Marcia A Rench; Hilde-Kari Guttormsen; Morven S Edwards; Dennis L Kasper
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

9.  Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.

Authors:  Christina R Phares; Ruth Lynfield; Monica M Farley; Janet Mohle-Boetani; Lee H Harrison; Susan Petit; Allen S Craig; William Schaffner; Shelley M Zansky; Ken Gershman; Karen R Stefonek; Bernadette A Albanese; Elizabeth R Zell; Anne Schuchat; Stephanie J Schrag
Journal:  JAMA       Date:  2008-05-07       Impact factor: 56.272

10.  Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.

Authors:  Carol J Baker; Marcia A Rench; Marisol Fernandez; Lawrence C Paoletti; Dennis L Kasper; Morven S Edwards
Journal:  J Infect Dis       Date:  2003-06-17       Impact factor: 5.226

View more
  14 in total

1.  Antibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.

Authors:  Jenny Herbert; Stephen Thomas; Charlotte Brookes; Claudia Turner; Paul Turner; Francois Nosten; Kirsty Le Doare; Michael Hudson; Paul T Heath; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

Review 2.  Early-onset neonatal sepsis.

Authors:  Kari A Simonsen; Ann L Anderson-Berry; Shirley F Delair; H Dele Davies
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

3.  Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus.

Authors:  Min Joo Choi; Ji Yun Noh; A-Yeung Jang; Hee Jin Cheong; Woo Joo Kim; Dae Jin Song; Geum Joon Cho; Min Jeong Oh; Yong Zhi; Ho Seong Seo; Joon Young Song
Journal:  Hum Vaccin Immunother       Date:  2019-11-15       Impact factor: 3.452

4.  Late and very late onset group B Streptococcus sepsis: one and the same?

Authors:  Joseph B Cantey; Courtney Baldridge; Rachel Jamison; Leticia A Shanley
Journal:  World J Pediatr       Date:  2014-01-25       Impact factor: 2.764

5.  Anti-group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection.

Authors:  Kirsty Le Doare; Lauren Allen; Beate Kampmann; Paul Trafford Heath; Stephen Taylor; Anneke C Hesseling; Andrew Gorringe; Christine Elizabeth Jones
Journal:  Vaccine       Date:  2014-12-24       Impact factor: 3.641

Review 6.  Increased Risk of Group B Streptococcus Invasive Infection in HIV-Exposed but Uninfected Infants: A Review of the Evidence and Possible Mechanisms.

Authors:  Nicolas Dauby; Mustapha Chamekh; Pierrette Melin; Amy L Slogrove; Tessa Goetghebuer
Journal:  Front Immunol       Date:  2016-11-16       Impact factor: 7.561

7.  Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy.

Authors:  Sonwabile Dzanibe; Gaurav Kwatra; Peter V Adrian; Sheila Z Kimaro-Mlacha; Clare L Cutland; Shabir A Madhi
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

8.  Serotype IV and invasive group B Streptococcus disease in neonates, Minnesota, USA, 2000-2010.

Authors:  Patricia Ferrieri; Ruth Lynfield; Roberta Creti; Aurea E Flores
Journal:  Emerg Infect Dis       Date:  2013-04       Impact factor: 6.883

9.  Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.

Authors:  Robert S Heyderman; Shabir A Madhi; Neil French; Clare Cutland; Bagrey Ngwira; Doris Kayambo; Robert Mboizi; Anthonet Koen; Lisa Jose; Morounfolu Olugbosi; Frederik Wittke; Karen Slobod; Peter M Dull
Journal:  Lancet Infect Dis       Date:  2016-02-08       Impact factor: 71.421

Review 10.  Vaccination of HIV-infected pregnant women: implications for protection of their young infants.

Authors:  Ziyaad Dangor; Marta C Nunes; Gaurav Kwatra; Sanjay G Lala; Shabir A Madhi
Journal:  Trop Dis Travel Med Vaccines       Date:  2017-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.